Project Grant F32AI203370

The National Institute of Allergy and Infectious Diseases awarded The Regents of the University of California, San Francisco $171,296 on February 3, 2027, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop methods for augmenting bacteriophages to improve their efficacy against Pseudomonas aeruginosa infections.

The funded research will develop methods to express soluble effectors during bacteriophage infection that degrade Pseudomonas' protective biofilm upon bacterial cell lysis and reduce the emergence of bacteriophage-resistant bacteria. The project will also identify bacteriophage genes that broaden the number of bacterial strains susceptible to phage therapy. This work addresses the growing crisis of antimicrobial resistance and the need for novel therapies against multidrug-resistant nosocomial pathogens, particularly medical device-associated infections.

Performance occurs in San Francisco, California, with a period of performance from February 3, 2027, through February 2, 2028. The assistance type is a Project Grant.